In a cohort of 52 patients representing a range of histopathology and tumor grades, Schuyer et al. found that patients expressing high levels of Bax in tumors had a significantly longer median survival (57 months) than patients with low Bax expression (18 months) [85]. The gene discussed is BAX; the disease is neoplasm.